Publications by authors named "B G Arnason"
Background: Pre-hospital tracheal intubation in trauma patients has recently been questioned. However, not only the trauma and patient characteristics but also airway provider competence differ between systems making simplified statements difficult.
Method: The study is a subgroup analysis of trauma patients included in the PHAST study.
Background: In multiple sclerosis (MS), immune up-regulation is coupled to subnormal immune response to interferon-β (IFN-β) and low serum IFN-β levels. The relationship between the defect in IFN signalling and acute and long-term effects of IFN-β on gene expression in MS is inadequately understood.
Methods: We profiled IFN-β-induced transcriptome shifts, using high-resolution microarrays on 227 mononuclear cell samples from IFN-β-treated MS Complete Responders (CR) stable for five years, and stable and active Partial Responders (PR), stable and active untreated MS, and healthy controls.
Background: Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon β.
Objective: To validate the proposed genetic markers and to identify new markers.
Early experience in MS generated concerns that interferon beta treatment might provoke onset or worsening of depression. The objective of the study was to compare depression incidence in relapsing-remitting MS patients receiving interferon beta-1b (IFNB-1b) or glatiramer acetate (GA) in the BEYOND trial. 891/897 (99 %) of English, French, Spanish and Italian speakers among 2244 patients randomized (2:2:1) to receive either IFNB-1b 500 µg, 250 µg, or GA 20 mg QD for 2-3.
View Article and Find Full Text PDFArticle Synopsis
- - Low levels of serum 25-hydroxyvitamin D (25[OH]D) are linked to a higher risk and worse progression of multiple sclerosis (MS), particularly in individuals with clinically isolated syndromes and early MS.
- - The study examined the relationship between 25(OH)D levels and disease course in 1,482 patients with relapsing-remitting MS receiving interferon beta-1b, involving regular monitoring over a two-year period.
- - Results indicated that lower average levels of 25(OH)D were associated with an increased number of new active lesions in the brain, indicating a detrimental effect on MS progression and disease activity.